Search Results

Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.

• Authors : Ozen, Ahmet (AUTHOR); Chongsrisawat, Voranush (AUTHOR); Sefer, Asena Pinar (AUTHOR)

Subjects: PROTEIN-losing enteropathy; CD55 antigen; PATIENT safetyTURKEY

• Source: Lancet. Feb2024, Vol. 403 Issue 10427, p645-656. 12p.

Record details

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

• Authors : Tuttle, Katherine R (AUTHOR); Hauske, Sibylle J (AUTHOR); Canziani, Maria Eugenia (AUTHOR)

Subjects: BOEHRINGER Ingelheim Pharmaceuticals Inc.; EMPAGLIFLOZIN; CHRONIC kidney failure

• Source: Lancet. Jan2024, Vol. 403 Issue 10424, p379-390. 12p.

Record details

Agricola

Record details

Agricola

Record details

Agricola

Record details

Agricola

Record details

Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.

• Authors : Molinelli, Elisa (AUTHOR); Simonetti, Oriana (AUTHOR)

Subjects: HIDRADENITIS suppurativa

• Source: Lancet. Jun2024, Vol. 403 Issue 10443, p2457-2459. 3p.

Record details

Agricola

Record details

Telomerase inhibition in haematological neoplasms—are we ready for primetime?

• Authors : Patnaik, Mrinal M (AUTHOR)

Subjects: TELOMERASE; TUMORS

• Source: Lancet. Jan2024, Vol. 403 Issue 10423, p220-222. 3p.

Record details

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.

• Authors : Shoamanesh, Ashkan (AUTHOR); Mundl, Hardi (AUTHOR); Smith, Eric E (AUTHOR)

• Source: Lancet. Sep2022, Vol. 400 Issue 10357, p997-1007. 11p.

Record details